In this two-part series, In Vivo will explore why organ on chip technology exists, the factors driving and limiting their application in drug development, and how companies can benefit from using them.

The French major is planning a Phase II trial of KT-474 in atopic dermatitis and hidradenitis suppurativa after the asset fared well in a small Phase I trial, although some analysts remain skeptical.

Public Company Edition: Third Harmonic hopes to double its money, raising up to $150m. Also, Halozyme priced a $625m note sale to retire debt and repurchase shares, while Viridian raised $270m in an offering after positive early data, and Clarus cut jobs while Endo finalized a restructuring plan.

Kymera has seen its share price fall more than 30% this week as investors struggle to gauge how much future market potential targeted protein degraders will have.